Clik here to view.
Another approved drug may leave the market
Bevacizumab Treatment for Solid Tumors, February 2, 2011, Hayes 305 (5): 506 — JAMA Avastin is a really expensive (think 50K a year) and dangerous (people die more often) drug that has been shown to...
View ArticleClik here to view.
Of exceptional importance – connecting patients to research
For quite some time, I’ve been very interested in the disconnect between the research being undertaken and the questions that people (especially patients and doctors) need answered. There is a huge...
View ArticleClik here to view.
Who creates the clinical evidence for cholesterol-lowering drugs?
Last week the US Food and Drug Administration released new warnings about the use of statins for patients in the United States. The warnings that have been added to labels in the US come from worries...
View ArticleClik here to view.
Learning from “Learning from Hackers”
Alongside colleagues (Enrico Coiera and Richard Day) from here in Sydney and (Kenneth Mandl) from near Boston in the US, I wrote an article for Science Translational Medicine in which we related the...
View ArticleClik here to view.
Neuropsych trials involving kids are designed differently when funded by the...
Over the short break that divided 2013 and 2014, we had a new study published looking at the designs of neuropsychiatric clinical trials that involve children. Because we study trial registrations and...
View ArticleEnsuring safe and effective drugs: who can do what it takes?
A nice editorial about the kinds of data available from industry-funded clinical trials, which was published yesterday in the BMJ and written by an inter-continental group of authors.Ensuring safe and...
View Article